Clinical Trial Update: Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a phase 1/2 study evaluating the combination of Revlimid (lenalidomide), Velcade (bortezomib), and Doxil (liposo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Revlimid (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-09-10